Jenner & Block Partners Aaron A. Barlow, Louis E. Fogel, Paul D. Margolis and Steven R. Trybus will speak at the American Conference Institute’s Paragraph IV Disputes Master Symposium that the firm is sponsoring in Chicago. Mr. Barlow’s session will feature a survey of recent at-risk launches and a risk-benefits analysis of launching at risk during the trial or appeal period based on current at-risk outcomes. Titled “Assessing the True Measure of Damages in At-Risk Launch Scenario,” that session will be held at 3 pm on October 1. Mr. Trybus’ session will explore the use and utility of petitions for Inter Partes Review (IPR), Post Grant Review (PGR) and Covered Business Method Patent Review (CBM). Titled “PTO Proceedings Update: The Continuing Use of IPR, PGR and CBM Review in the Hatch-Waxman Arena,” that session will be held at 2:15 pm on September 30. Mr. Fogel and Mr. Margolis will lead a half-day workshop that is focused on biosimilars (generic biological drugs) patent litigation. Titled “Biosimilars Boot Camp for the Paragraph IV Litigator,” that workshop will be held from 1-4:30 pm on October 2. The symposium will be held at the InterContinental Chicago.
Mr. Barlow has focused his practice almost exclusively on patent litigation. He has worked on patent infringement cases involving pharmaceuticals, chemicals, computer software, electronics, biotechnology products and medical devices.
Mr. Fogel counsels life sciences clients in all aspects of complex patent litigation to help businesses achieve their strategic goals. He has litigated across a range of technologies, including biotechnology, pharmaceuticals, medical devices, and consumer electronics.
Mr. Margolis is a litigator who focuses on intellectual property. Clients seek his help with patent infringement actions in a wide range of scientific fields, including chemical, pharmaceutical, biomedical, electronics, mechanical and agricultural.
Mr. Trybus concentrates on patent infringement litigation in court and in PTAB proceedings. He is experienced in a variety of technologies including pharmaceuticals and medical devices to electronics, software, mechanical devices and polymers.